Drugs / GSK3008356
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02742766 | Mar 2016 → Jun 2017 | — | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK3008356 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02742766 ↗ |
| Route | Oral | “This intervention is available as 0.5, 1, 5, and 25 mg white oral tablet.” NCT02742766 ↗ |